François Raffi

14.6k total citations · 1 hit paper
208 papers, 6.3k citations indexed

About

François Raffi is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, François Raffi has authored 208 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 165 papers in Infectious Diseases, 139 papers in Virology and 45 papers in Epidemiology. Recurrent topics in François Raffi's work include HIV Research and Treatment (135 papers), HIV/AIDS drug development and treatment (132 papers) and HIV/AIDS Research and Interventions (103 papers). François Raffi is often cited by papers focused on HIV Research and Treatment (135 papers), HIV/AIDS drug development and treatment (132 papers) and HIV/AIDS Research and Interventions (103 papers). François Raffi collaborates with scholars based in France, United States and Canada. François Raffi's co-authors include Bruno Spire, Catherine Leport, Nathan Clumeck, Geneviève Chêne, A. Pozniak, Jean‐Paul Moatti, Ségolène Duran, Patrizia Carrieri, Vincent Le Moing and Clotilde Allavena and has published in prestigious journals such as New England Journal of Medicine, The Lancet and PLoS ONE.

In The Last Decade

François Raffi

204 papers receiving 6.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

2013 404 citations François Raffi, Anita Rachlis et al. The Lancet profile →

Peers

Countries citing papers authored by François Raffi

Since Specialization

Citations

This map shows the geographic impact of François Raffi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by François Raffi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites François Raffi more than expected).

Fields of papers citing papers by François Raffi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by François Raffi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by François Raffi. The network helps show where François Raffi may publish in the future.

Co-authorship network of co-authors of François Raffi

This figure shows the co-authorship network connecting the top 25 collaborators of François Raffi. A scholar is included among the top collaborators of François Raffi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with François Raffi. François Raffi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens 2024 ·Vaccines ·(unknown), Jie Min Lam, Jehad Abdalla, Samira Bell, (unknown), Tal Brosh‐Nissimov, John S. Gill, Ghady Haidar, Michael Hoerger, ‪Yasmin Maor‬‏, Antonio Pagliuca, François Raffi, (unknown), Dorry L. Segev, (unknown), Lennard Y. W. Lee	2
2	Too fast to stay on track? Shorter time to first anti-retroviral regimen is not associated with better retention in care in the French Dat’AIDS cohort 2019 ·PLoS ONE ·Lise Cuzin, (unknown), Cyrille Delpierre, Clotilde Allavena, M.A. Valantin, D. Rey, Pierre Delobel, (unknown), François Raffi, André Cabié, (unknown)	13
3	Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients 2017 ·Journal of Hepatology ·Patrizia Carrieri, Camélia Protopopescu, Fabienne Marcellin, Silvia Rosellini, Linda Wittkop, Laure Esterle, David Zucman, François Raffi, Éric Rosenthal, Isabelle Poizot‐Martin, Dominique Salmon‐Céron, François Dabis, Bruno Spire	18
4	Sub-Saharan African migrants have slower initial CD4+ cell recovery after combined antiretroviral treatment initiation than French natives 2017 ·AIDS ·Rémonie Seng, (unknown), Pierre‐Marie Girard, Laurent Cotte, Agnès Meybeck, François Raffi, (unknown), Yazdan Yazdanpanah, Cécile Goujard, Rosemary Dray‐Spira, Laurence Meyer	4
5	Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk 2017 ·AIDS ·José M. Gatell, Lambert Assoumou, Graeme Moyle, Laura Waters, Margaret Johnson, Peré Domingo, Julie Fox, Estebán Martínez, (unknown), Giovanni Guaraldi, Mar Masiá, Mark Gompels, Christoph Stephan, Éric Florence, Stefan Eßer, François Raffi, Anton Pozniak	54
6	Switching regimens in virologically suppressed HIV‐1‐infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)‐containing regimens 2016 ·HIV Medicine ·François Raffi, (unknown), Giuseppe Nunnari, (unknown), Laura Waters	24
7	Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial 2016 ·The Lancet HIV ·Joel E. Gallant, Eric S. Daar, François Raffi, Cynthia Brinson, Peter Ruane, Edwin DeJesus, Margaret Johnson, Nathan Clumeck, Olayemi Osiyemi, (unknown), Javier O Morales-Ramirez, Mingjin Yan, Michael E. Abram, Andrew Plummer, Andrew Cheng, Martin S. Rhee	127
8	Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. 2014 ·The Lancet Neurology ·François Raffi, Abdel G. Babiker, Laura Richert, Jean‐Michel Molina, Elizabeth C. George, Andrea Antinori, José Ramón Arribas, Jesper Grarup, Fleur Hudson, Christine Schwimmer, Juliette Saillard, Cédrick Wallet, (unknown), Clotilde Allavena, Remko van Leeuwen, Jean‐François Delfraissy, Stefano Vella, Geneviève Chêne, Anton Pozniak	1
9	A liquid chromatography–tandem mass spectrometry assay for quantification of rilpivirine and dolutegravir in human plasma 2014 ·Journal of Chromatography B ·Matthieu Grégoire, Guillaume Deslandes, Christian Renaud, Régis Bouquié, Clotilde Allavena, François Raffi, Pascale Jolliet, Éric Dailly	25
10	Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study breakdown → 2013 ·The Lancet ·François Raffi, Anita Rachlis, Hans‐Jürgen Stellbrink, W. D. Hardy, Carlo Torti, Chloe Orkin, Mark Bloch, Daniel Podzamczer, Vadim Pokrovsky, Federico Pulido, (unknown), David M. Margolis, Clare Brennan, Sherene Min	404
11	Effect of Efavirenz, Nevirapine, Etravirine, and Raltegravir Administration on the Pharmacokinetics of Ritonavir-Boosted Darunavir in a Population of HIV-Infected Patients 2012 ·AIDS Research and Human Retroviruses ·Éric Dailly, Clotilde Allavena, Régis Bouquié, Guillaume Deslandes, François Raffi, Pascale Jolliet	1
12	Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults 2009 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Sharon Walmsley, Anchalee Avihingsanon, Jihad Slim, Douglas Ward, Kiat Ruxrungtham, Jason Brunetta, U. Fritz Bredeek, Dushyantha Jayaweera, (unknown), Peter J. Larson, Malte Schütz, François Raffi	76
13	Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine 2008 ·Journal of Antimicrobial Chemotherapy ·Jade Ghosn, Marie‐Laure Chaix, Gilles Peytavin, (unknown), Julie Galimand, Pierre‐Marie Girard, François Raffi, Isabelle Cohen-Codar, Jean‐François Delfraissy, C Rouzioux	29
14	Enfuvirtide, premier inhibiteur de fusion dans le traitement de l'infection par le virus de l'immunodéficience humaine : mécanisme d'action et pharmacocinétique 2004 ·Médecine et Maladies Infectieuses ·François Raffi	3
15	Plasma Levels of Indinavir and Nelfinavir at Time of Virologic Response May Have a Different Impact on the Risk of Further Virologic Failure in HIV-Infected Patients 2003 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Vincent Le Moing, Gilles Peytavin, Valérie Journot, Jacqueline Cottalorda, E Bouvet, Geneviève Chêne, Marie Préau, Corinne Merle De Boever, Catherine Leport, François Raffi	7
16	Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen 2002 ·AIDS ·Vincent Le Moing, Geneviève Chêne, Patrizia Carrieri, Ahmadou Alioum, Françoise Brun‐Vézinet, Lionel Piroth, (unknown), Jean‐Paul Moatti, François Raffi, Catherine Leport	141
17	Self-Reported Symptoms After Initiation of a Protease Inhibitor in HIV-Infected Patients and Their Impact on Adherence to HAART 2001 ·HIV Clinical Trials ·Ségolène Duran, Bruno Spire, François Raffi, (unknown), Damien Bouhour, Valérie Journot, Valérie Cailleton, (unknown), Jean-Paul Moatti, (unknown)	193
18	Mortality in a Cohort of HIV-Infected Adults Started on a Protease Inhibitor-Containing Therapy 2001 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Charlotte Lewden, François Raffi, Geneviève Chêne, A Sobel, C. Leport	31
19	Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine 1999 ·Clinical Pharmacology & Therapeutics ·C. Michelet, Éric Bellissant, Annick Ruffault, C. Arvieux, Jean‐François Delfraissy, François Raffi, Dominique Bazin, Isabelle Renard, Véronique Sebille, J P Chauvin	6
20	Arthrite septique à Pasteurella multocida. Traitement par une fluoroquinolone. 1989 ·La Presse Médicale ·François Raffi, Philippe Poirier, Alain Reynaud	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact